-- Treatment with venlafaxine is associated with sustained increases in
blood pressure (BP) in some patients. Postmarketing cases of elevated
BP requiring immediate treatment have been reported. Pre-existing
hypertension should be controlled. Regular BP monitoring is
-- SSRIs and SNRIs, including EFFEXOR XR, may increase the risk of
bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and
other anticoagulants may add to this risk.
-- Mydriasis has been reported in association with venlafaxine; therefore,
patients with raised intraocular pressure or those at risk of acute
narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
-- Abrupt discontinuation or dose reduction has been associated with
discontinuation symptoms. Patients should be counseled on possible
discontinuation symptoms and monitored while discontinuing the drug;
the dose should be tapered gradually.
-- The most common adverse events reported in EFFEXOR XR short-term
placebo-controlled MDD, generalized anxiety disorder (GAD), social
anxiety disorder (SAD), and/or panic disorder (PD) trials (incidence
greater than or equal to 10% and greater than or equal to 2x that of
placebo) were anorexia, asthenia, constipation, dizziness, dry mouth,
ejaculation problems, impotence, insomnia, nausea, nervousness,
somnolence, and sweating.
For full prescribing information for EFFEXOR XR, please go to http://www.EffexorXR.com.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved